KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) EBIT (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed EBIT for 17 consecutive years, with -$2.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, EBIT rose 43.35% to -$2.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$4.6 billion, a 79.38% increase, with the full-year FY2025 number at -$4.6 billion, up 79.38% from a year prior.
  • EBIT was -$2.6 billion for Q4 2025 at Bristol Myers Squibb, down from -$320.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $204.0 million in Q1 2023 to a low of -$14.4 billion in Q1 2024.
  • A 5-year average of -$1.7 billion and a median of -$773.0 million in 2022 define the central range for EBIT.
  • Peak YoY movement for EBIT: surged 126.02% in 2023, then crashed 7182.35% in 2024.
  • Bristol Myers Squibb's EBIT stood at -$498.0 million in 2021, then plummeted by 47.39% to -$734.0 million in 2022, then crashed by 45.91% to -$1.1 billion in 2023, then plummeted by 332.96% to -$4.6 billion in 2024, then soared by 43.35% to -$2.6 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's EBIT are -$2.6 billion (Q4 2025), -$320.0 million (Q3 2025), and -$1.6 billion (Q2 2025).